TARA at a glance
Protara Therapeutics, Inc. (TARA, SEC CIK 1359931) filed its latest 10-K annual report on March 10, 2026, a 10-Q quarterly report on November 6, 2026, an 8-K current report on November 6, 2026 and Form 4 insider filings as recently as July 1, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- As of September 30, 2026, 26 institutional investment managers tracked by SignalX reported holding Protara Therapeutics, Inc. (TARA) shares worth $60.5 million in 13F-HR filings.
- The most recent insider open-market sale reported on Form 4 was by Shefferman Jesse on June 29, 2026 of 215,687 shares at $4.09 per share.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Insiders · 90 days
- 0 buys · 0 sells
- No open-market trades
- 13F holders
- 26 funds
- $60.5M · −2 vs prior quarter
- Latest 8-K
- Nov 6, 2026
- Item 2.02
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Sep 30, 2026
Management Discussion & Analysis
- Revenue $0, unchanged YoY, with no product sales since inception
- Operating margin not meaningful: operating loss $23.2M vs $14.8M YoY
- R&D highest spend, $16.8M vs $9.6M, led by NMIBC expenses of $6.9M
- Cash and securities $143.1M vs $197.9M at December 31, 2025; operating cash use $55.2M
- ADVANCED-2 enrollment expected complete by end of 2026; interim THRIVE-3 results expected fourth quarter 2026
Risk Factors
- No material changes to risk factors disclosed in the December 31, 2025 Form 10-K
- Carried-forward risks remain applicable across regulatory, operational, competitive, and financial categories
AI summary of the TARA 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 2.02: Results of Operations and Financial Condition
- Protara announced financial results for the quarter ended September 30, 2026
- Full results and management commentary are in Exhibit 99.1, the accompanying earnings release
Item EX-99.1: Item EX-99.1
- TARA-002 NMIBC enrollment targeted for Q4 2026, a key catalyst for registrational ADVANCED-2 progress
- STARBORN-1 LM enrollment pushed to early Q1 2027, with rolling BLA submission still planned for 2H 2027
Item EX-99.1: Item EX-99.1
- Cash, cash equivalents and investments $161.9M at June 30, 2026, expected to fund operations into 2028
- ADVANCED-2 BCG-unresponsive enrollment targeted for 4Q 2026, a key NMIBC registrational milestone
Item 2.02: Results of Operations and Financial Condition
- Protara announced financial results for the quarter ended June 30, 2026
- Detailed results and management commentary are contained in Exhibit 99.1, the attached press release
Item 5.02: Departure/Appointment of Directors or Principal Officers
- Chief Medical Officer Leonardo Viana Nicacio resigned effective June 26, 2026 to pursue other opportunities
- Medical leadership responsibilities transferred to Lead Medical Director Carla Beckham
AI summaries of TARA 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for TARA
Don't miss the next TARA filing
- Alerts as it files. A push when TARA files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut TARA, by share count.
- Ask anything. An AI agent that reads every TARA filing and answers with sources.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Shefferman Jesse | G | Jun 30, 2026 | 4,000 | - |
| Shefferman Jesse | G | Jun 30, 2026 | 14,000 | - |
| Shefferman Jesse | G | Jun 30, 2026 | 7,000 | - |
| Shefferman Jesse | G | Jun 30, 2026 | 5,000 | - |
| Shefferman Jesse | M | Jun 29, 2026 | 215,687 | $1.91 |
| Shefferman Jesse | Sell | Jun 29, 2026 | 215,687 | $4.09 |
| Shefferman Jesse | M | Jun 29, 2026 | 215,687 | - |
| BESHAR LUKE M | A | Jun 15, 2026 | 31,000 | - |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Operating Income | -$43.6M | -$49.2M | -$64.5M |
| Net Income | -$40.4M | -$44.6M | -$57.4M |
| Balance Sheet | |||
| Total Assets | - | $181.5M | $209.5M |
| Equity | $68.3M | $167.1M | $196.4M |
| ROE | -59.2% | -26.7% | -29.2% |
| Per Share | |||
| EPS | $-3.57 | $-2.17 | $-1.34 |
| Cash Flow | |||
| Operating CF | -$37.6M | -$35.8M | -$56.4M |
| CapEx | $45K | $63K | $94K |
Source: XBRL data in Protara Therapeutics, Inc. (TARA)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q3 2026Aggregate TARA share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q3 2026 | 26 | $60.5M |
| Q2 2026 | 28 | $70.3M |
| Q1 2026 | 26 | $86.8M |
| Q4 2025 | 25 | $58.4M |
| Q3 2025 | 23 | $38.2M |
| Q2 2025 | 21 | $25.2M |
| Q1 2025 | 14 | $22.9M |
| Q4 2024 | 11 | $25.5M |
- Ameriprise Financial+1.06M (+1890%)
- Citadel Advisors LLC+854.7K (+69%)
- Renaissance Technologies LLC+280.3K (+111%)
- Two Sigma Investments+172.3K (+247%)
- Blackstone Group+101.0K (+4%)
- Goldman Sachs Group−386.5K (-71%)
- Morgan Stanley−297.4K (-58%)
- AQR Capital Management−171.7K (-82%)
- Vanguard Portfolio Management LLC−128.1K (-26%)
- Wells Fargo & Co−43.4K (-80%)
- FMR LLC (Fidelity)−68.2K
- Prudential Financial−50.7K
Source: 13F-HR filings on SEC EDGAR (aggregated from 174 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
TARA filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-Q quarterly reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 10-Q | Nov 6, 2026 | Sep 30, 2026 | Analysis | |
| 8-K | Nov 6, 2026 | - | Analysis | - |
| 10-Q | Aug 11, 2026 | Jun 30, 2026 | Analysis | |
| 8-K | Aug 11, 2026 | - | Analysis | - |
| 4 | Jul 1, 2026 | - | - | - |
| 8-K | Jun 29, 2026 | - | Analysis | - |
| 4 | Jun 16, 2026 | - | - | - |
| 4 | Jun 16, 2026 | - | - | - |
| 4 | Jun 16, 2026 | - | - | - |
| 4 | Jun 16, 2026 | - | - | - |
| 4 | Jun 16, 2026 | - | - | - |
| 4 | Jun 16, 2026 | - | - | - |
| 4 | Jun 16, 2026 | - | - | - |
| 4 | Jun 16, 2026 | - | - | - |
| 8-K | Jun 15, 2026 | - | Analysis | - |
| 8-K | May 13, 2026 | - | Analysis | |
| 10-Q | May 13, 2026 | Mar 31, 2026 | Analysis | |
| SC 13G | Apr 27, 2026 | - | - | |
| 4 | Apr 9, 2026 | - | - | - |
| 4 | Apr 2, 2026 | - | - | - |
| 8-K | Mar 30, 2026 | - | - | - |
| 10-K | Mar 10, 2026 | Dec 31, 2025 | - | |
| 8-K | Mar 10, 2026 | - | Analysis | - |
| SC 13G | Mar 2, 2026 | - | - | |
| 8-K | Feb 24, 2026 | - | Analysis | - |
Related Health Care companies
- FDMT · 4D Molecular Therapeutics, Inc.Biological Products, (No Diagnostic Substances)
- ADPT · Adaptive Biotechnologies CorpBiological Products, (No Diagnostic Substances)
- ADMA · ADMA BIOLOGICS, INC.Biological Products, (No Diagnostic Substances)
- ALEC · Alector, Inc.Biological Products, (No Diagnostic Substances)
- ALLO · Allogene Therapeutics, Inc.Biological Products, (No Diagnostic Substances)
- AMGN · AmgenBiological Products, (No Diagnostic Substances)
- AVXL · ANAVEX LIFE SCIENCES CORP.Biological Products, (No Diagnostic Substances)
- APGE · Apogee Therapeutics, Inc.Biological Products, (No Diagnostic Substances)
TARA SEC filings: frequently asked questions
Which institutions hold TARA stock?
As of September 30, 2026, the largest Protara Therapeutics, Inc. (TARA) holders among the 13F filers tracked by SignalX were BlackRock ($11.3 million), Millennium Management ($9.4 million), Blackstone Group ($7.2 million), Vanguard Capital Management LLC ($7.0 million), Citadel Advisors LLC ($6.4 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What did TARA report in its latest 8-K?
Protara Therapeutics, Inc. (TARA) filed an 8-K on November 6, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Protara announced financial results for the quarter ended September 30, 2026.
What are the latest TARA SEC filings?
Protara Therapeutics, Inc. (TARA) filed its latest 10-K annual report on March 10, 2026, a 10-Q quarterly report on November 6, 2026, an 8-K current report on November 6, 2026 and a Form 4 insider filing on July 1, 2026.
What is TARA's SEC CIK number?
Protara Therapeutics, Inc. (TARA)'s SEC Central Index Key (CIK) is 1359931. EDGAR lists every TARA filing under that number.
Ask anything about TARA
The research agent reads TARA's filings, financials, insider trades and 13F holders, then answers with sources.